ARQT Q1 2026: ZORYVE Revenue Hits $105.4M, Up 65% YoY as EPS Misses Estimate

Arcutis Biotherapeutics (NASDAQ: ARQT) shares rose $0.75, or 3.20%, to $24.17 on the back of its Q1 2026 results, which showed $105.4 million in net product revenue for ZORYVE® — a 65% increase year-over-year. While the top line comfortably cleared the $101.3 million analyst consensus, EPS of $(0.09) missed the $(0.06) estimate, tempering some of the enthusiasm.

Q1 2026 At a Glance

• Net product revenue (ZORYVE): $105.4M vs. consensus estimate of $101.3M — a beat
• EPS: $(0.09) vs. consensus of $(0.06) — missed by 50%
• Year-over-year EPS improvement: Loss narrowed 55% from $(0.20) in Q1 2025
• Sequential revenue change: Down 17% vs. Q4 2025, consistent with typical Q1 seasonal patterns
• Gross margin: 90.2%
• Operating margin: 14.2%
• Revenue growth (YoY): 81.5%
• Market cap: $3.0B | Forward P/E: 20.0x
• SEC 8-K filing date: 2026-05-06 (Item 9.01)

What Drove the Results

The 65% year-over-year revenue increase reflects sustained commercial demand for ZORYVE, the company's flagship dermatology franchise. Management noted that the 17% sequential decline from Q4 2025 is attributable to typical first-quarter dynamics, rather than any deterioration in underlying demand — a pattern common across specialty pharmaceutical launches.

On profitability, the 90.2% gross margin underscores the favorable economics of the ZORYVE product line. The 14.2% operating margin and a meaningful narrowing of the per-share loss — from $(0.20) a year ago to $(0.09) — suggest the company is making measurable progress toward profitability, even as the net margin remains slightly negative at -4.3%.

Wall Street View

Analyst sentiment on (NASDAQ: ARQT) remains firmly constructive. As of May 1, 2026, the consensus stands at 4 Strong Buy, 8 Buy, and 2 Hold ratings, with no Sell or Strong Sell calls. Notably, this distribution is unchanged from the April 1, 2026 prior period, indicating that the Q1 results have not prompted any meaningful re-rating in either direction among covering analysts.

Investor Takeaway

Arcutis Biotherapeutics (NASDAQ: ARQT) delivered a revenue beat driven by genuine commercial momentum in ZORYVE, while the EPS shortfall reflects ongoing investment in growth rather than a structural profitability concern, given the rapid improvement in per-share losses year-over-year. The unchanged analyst consensus — heavily skewed toward Buy — suggests the Street views the Q1 results as broadly consistent with the company's trajectory. Investors will likely focus on whether the 65% year-over-year revenue growth rate is sustainable as the ZORYVE franchise matures through the remainder of 2026.